FFPRHC guidance (October 2003) first prescription of combined oral contraception

Journal of Family Planning and Reproductive Health Care

Volumn 29, Issue 4, 2003, Pages 209-223

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FEMODENE ED; LOGYNON ED; MESTRANOL PLUS NORETHISTERONE; MICROGYNON 30 ED; ORAL CONTRACEPTIVE AGENT; TRI MINULET;

CLINICAL PRACTICE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE QUALITY; HUMAN; MEDICAL PRACTICE; ORAL CONTRACEPTION; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; REPRODUCTIVE HEALTH; REVIEW;

EID: 0142056198     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118903101198114     Document Type: Review

References (128)

1. Faculty of Family Planning and Reproductive Health Care (FFPRHC). First prescription of combined oral contraception: recommendations for clinical practice. Br J Fam Plann 2000; 26: 27-38.
2. Dawe F, Meltzer H. Contraception and sexual health, 2001. Office for National Statistics. London, UK: Her Majesty's Stationery Office (HMSO), 2003, i-50.
3. World Health Organization (WHO). Medical eligibility criteria for contraceptive use. Geneva, Switzerland: WHO, 2000.
4. Croft P, Hannaford P. Risk factors for adults myocardial infarction in women - evidence from RCGP Oral Contraceptive Study. BMJ 1989; 298: 165-168.
5. World Health Organization (WHO). WHO Collaborative Study of Cardiovascular Disease and Sex Steroid Hormone Contraception. Ischaemic stroke and combined oral contraception: results of an international, multicentre, case-control study. Lancet 1996; 348: 498-505.
6. The International Headache Society Task Force on Combined Oral Contraceptives and Hormone Replacement Therapy. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalagia 2000; 20: 155-156.
7. Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000; 321: 1190-1195.
8. Farmer RDT, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Pharmacol 2000; 49: 580-590.
9. Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-191.
10. Department of Health. Obesity - Prodigy Guidance 2002. London, UK: Department of Health, 2002.
11. British National Formulary. London, UK: British Medical Association and the Royal Pharmaceutical Society of Great Britain, March 2003.
12. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five year national case-control study. Contraception 2002; 65: 187-196.
13. World Health Organization (WHO). WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 346: 505-510.
14. Gupta S, Hannaford P. Combined oral contraceptives - myocardial infarction, stroke and venous thromboembolism. Inserted into the Journal of Family Planning and Reproductive Health Care 1999; Review No. 99/01.
15. Endrikat J, Gerlinger C, Cronin M, et al. Blood pressure stability in a normotensive population during intake of monophasic oral contraceptive intake containing 20 microgram ethinyl oestradiol and 75 microgram desogestrel. Eur J Contracept Reprod Health Care 2001;6:159-166.
16. Cosmi B, Legnani C, Bernardi F, et al. Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study. BMJ 2001; 322: 1024-1025.
17. Vandenbroucke JP, van der Meer F, Helmerhorst FM, et al. Family history and risks of venous thromboembolism with oral contraception (Letter). BMJ 2001; 323: 752.
18. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1993; 353: 1167-1173.
19. The Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Prestbury, UK: International Headache Society, 1998; 1-55.
20. MacGregor EA. Hormonal contraception and migraine (FFPRHC FACT). J Fam Plann Reprod Health Care 2001; 27: 49-52.
21. Lidegaard O. Oral contraception and risk of cerebral thromboembolic attack: results of a case-control study. BMJ 1993; 306: 956-963.
22. Chang CL, Donaghy M, Poulter NR, for the WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. BMJ 1999; 318: 13-18.
23. Akpoviroro J, Mangalam M, Kenkins N, et al. Binding of contraceptive steroids medroxyprogesterone acetate and ethinyl oestradiol in the blood of various species. J Steroid Biochem 1981; 14: 493-498.
24. American Academy of Neurology. Practice parameter: management issues for women with epilepsy. Report of the Quality Standards Subcommittee of the American Journal of Neurology, 2002.
25. Elliman A. Interactions with hormonal contraception. J Fam Plann Reprod Health Care 2000; 26: 109-111.
26. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263-272.
27. Scottish Intercollegiate Guideline Network (SIGN). Contraception, pregnancy and HRT (Chapter 4). Diagnosis and management of epilepsy in adults. Guideline No. 70. Edinburgh, UK: SIGN, 2003.
28. Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 1990; 163: S2114-S2119.
29. Kisicki J. Bioequivalence of Norethin and Ortho-Novum in health females. Adv Ther 1989; 6: 261-268.
30. Clinical Effectiveness Unit. Short scientific review: use of rifampicin and contraceptive steroids. Br J Fam Plann 1999; 24: 169-170.
31. Committee on Safety of Medicines (CSM). Reminder: St John's Wort (Hypericum perforatum) interactions. Current Problems in Pharmacovigilance 26 (May), 1-8. 2000. London, UK: Medicines Control Agency.
32. World Health Organization (WHO). Selected practice recommendations for contraceptive use. Geneva, Switzerland: WHO, 2002.
33. British Society for Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-528.
34. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
35. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
36. Lakasing L, Khamashta M. Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: what advice should we be giving. J Fam Plann Reprod Health Care 2001; 27: 7-12.
37. British Society for Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-715.
38. Scottish Intercollegiate Guidelines Network (SIGN) Secretariat. Chlamydia trachomatis - summary and conclusions of CMO's Expert Advisory Group. London, UK: Department of Health, 1998; 1-22.
39. Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses Health Study. Ann Int Med 1994; 120: 821-826.
40. Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from the Royal College of General Practitioners' oral contraception study. BMJ 1999; 318: 96-100.
41. Edwards A, Elwyn G, Mulley AI. Explaining risks: tuming numerical data into meaningful pictures. BMJ 2002; 324: 827-830.
42. Edwards JE, Oldman A, Smith L, et al. Women's knowledge of, and attitudes to, contraceptive effectiveness and adverse health effects. J Fam Plann Reprod Health Care 2000; 26: 73-80.
43. Berry DC, Raynor DK, Knapp P, et al. Official warnings on thromboembolism risk with oral contraceptives fail to inform users adequately. Contraception 2002; 66: 305-307.
44. Calman K, Royston G. Risk language and dialects. BMJ 1997; 315: 939-942.
45. Bennett P. Communicating about risks to public health: pointers to good practice. London, UK: Department of Health, 2003.
46. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea (Cochrane Review). In The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
47. Hendrix SL, Alexander NJ. Primary dysmenorrhoea treatment with a desogestrel-containing low dose oral contraceptive. Contraception 2002;66:393-399.
48. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding (Cochrane Review). The Cochrane Library, Issue 1, 2003.
49. Fraser I, McCarron G. Randomised trial of two hormonal and two prostaglandin inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991; 31: 66-70.
50. Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. (Cochrane Review). In The Cochrane Library, Issue 3, 2003. Oxford: Update Software..
51. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Hormonal contraception and postmenopausal hormonal therapy. Lyons, France: WHO IARC, 1999.
52. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestogen dose and use characteristics of oral contraceptives. Am J Epidemiol 2000; 152: 233-241.
53. Holt VL, Daling JR, McKnight B, et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992; 79: 529-533.
54. Lanes SF, Birman B, Walker AM, et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992; 166: 956-961.
55. Westhoff C, Britton JA. Gammon MD, et al. Oral contraceptives and benign ovarian tumours. Am J Epidemiol 2000; 152: 242-246.
56. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993; 82: 931-935.
57. Cancer and Steroid Hormones (CASH). Combined oral contraceptive use and risk of endometrial cancer. JAMA 1987; 257: 796-800.
58. Fernandez E, Vecchia CL, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001; 84: 722-727.
59. Martinez ME, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use and risk of colorectal cancer. Cancer Epidemiol 1997; 6: 1-5.
60. DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996; 174: 15-20.
61. Berenson AB, Radecki RM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Am J Obstet Gynecol 2001; 98: 576-582.
62. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, et al. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002; 65: 407-410.
63. Michaelsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fracture: case-control study. Lancet 1999; 353: 1481-1484.
64. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003; 188: 1158-1160.
65. Leyden J, Shalita A, Hordinskly M, et al. Efficacy of a low dose oral contraceptive containing 20 microg of ethinyl oestradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized placebo-controlled trial. J Am Acad Dermatol 2002; 47: 399-409.
66. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990; 43: 1221-1230.
67. Burkman RT, Collins JA, Shulman LP, et al. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001; 185: 4-12.
68. Panser LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991; 43: 91-99.
69. Kahn LS. Oral contraceptives and mood. Exp Opin Pharmacother 2001; 2: 1367-1382.
70. World Health Organization (WHO). WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen containing oral contraceptives on venous thromboembolism. Lancet 1995; 346: 1575-1582.
71. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169-181.
72. Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002; 81: 482-490.
73. Committee on Safety of Medicines (CSM). Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Current Problems in Pharmacovigilance 1999; 25: 1-2.
74. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146.
75. Kenneth A, Bauer MD. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Int Med 2001; 135: 367-373.
76. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-88.
77. Lewis MA, Heinemann L, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens; role of bias in observational research. Contraception 1996; 54: 5-13.
78. Westhoff C. Oral Contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making? Contraception 1996; 54: 1-3.
79. Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003; 326: 257.
80. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358(9291): 1427-1429.
81. Committee on Safety of Medicines (CSM). Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). Current Problems in Pharmacovigilance 2002; 28: 9-10.
82. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
83. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032.
84. Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284: 1791-1799.
85. Narod SA, Dube MP, Klijn J. Oral contraceptives and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773-1770.
86. UK Govemment. National Statistics. Cervical cancer, key statistics. 2003 www.statistics.gov.uk
87. Smith JS, Green J. Cervical cancer and use of hormonal contraception: a systematic review. Lancet 2003; 361: 1159-1167.
88. Moreno V, Bosch FX, Munoz N. Effects of oral contraceptives on risk of cervical cancer in women with human papilloma virus infection: the IARC multicentric case-control study. Lancet 2002; 399(9312): 1085-1092.
89. Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 1999; 318: 1244-1245.
90. Tuckey J. Combined oral contraception and cancer (FFPRHC FACT). Br J Fam Plann 2000; 26: 237-240.
91. Royal College of Obstetricians and Gynaecologists (RCOG). Greentop guideline: the management of gestational trophoblastic disease. Clinical Green Top Guidelines 18. London, UK: RCOG, 2000.
92. Saleh WA, Burkman RT, Zacur HA, et al. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol 1993; 168: 1740-1747.
93. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993; 100: 832-888.
94. Comparato MR, Yabur JA, Bajares M. Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 microgram ethinyl estradiol and 150 microgram desogestrel in Latin-American women. Adv Contracept 1998; 14: 15-26.
95. Bannemerschult R, Hanker JP, Wunsch C, et al. A multicentre, uncontrolled clinical investigation of the contraceptive efficacy, cycle control and safety of a new low dose oral contraceptive containing 20 mug ethinyl estradiol and 100 mug levonorgestrel over six treatment cycles. Contraception 1997; 56: 285-290.
96. Gallo MF, Grimes DA, Schulz KF, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2003: 2: CD003987.
97. Killick SR, Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycle. Fertil Steril 1987; 48: 409-413.
98. Hatcher RA, Trussell J, Stewart F, et al. Contraceptive technology (17th edn). New York, NY: Ardent Media, 1998.
99. Wysocki S, Schnare SM. Evaluating the efficacy of combined hormonal contraceptives. 2003. www.npwh.org/combined-hormonal/
100. Burkman RT. Clinical pearls: factors affecting reported contraceptive efficacy rates in clinical studies. Int J Fertil 2002; 47: 153-161.
101. Danforth DR, Hodgen GD. "Sunday start" multiphasic oral contraception: ovulation prevention and delayed follicular atresia in primates. Contraception 1989; 39: 321-330.
102. Schwarz JL, Creinin MD, Pymar HC, et al. Predicting risk of ovulation in new start oral contraceptive users. Am Coll Obstet Gynecol 2002; 99: 177-182.
103. Miller L, Notter K. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771-778.
104. Treloar AE, Boynton RE, Borchild MD, et al. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12: 77-126.
105. Sherman BM, Krorenman SG. Measurement of plasma LH, FSH, estradiol and progesterone in disorders of human menstrual cycle: the short cycle. J Clin Endocrinol Metab 1974; 38: 89-93.
106. Royal College of Obstetricians and Gynaecologists (RCOG). The care of women requesting induced abortion. No. 7, 1-70. London, UK: RCOG, 2000.
107. Elomaa K, Lahteenmaki.P. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment. Contraception 1999; 60: 275-279.
108. van Heusden AM. Fauser BCJM. Activity of the pituitary ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 1999; 59: 237-243.
109. Smith SK, Kirkman RJE, Arce BB, et al. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Contraception 1986; 34: 513-522.
110. Elomaa K, Rolland R, Brosens I, et al. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation. Am J Obstet Gynecol 2002; 179: 41-46.
111. Killick SR, Bancroft K, Oelbaum S, et al. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept 1990; 6: 33-40.
112. Aubeny E, Buhler M, Colau JC, et al. Oral contraception: patterns of non-compliance. The Compliance Study. Eur J Contracept Reprod Health Care 2002; 7: 155-161.
113. Glasier A, Smith KB, van der Spuy ZM, et al. Amenorrhoea associated with contraception - an international study on acceptability. Contraception 2003; 67: 1-8.
114. Kwiecien M, Edelman A, Nichols MD. et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 9-13.
115. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. Contraception 1999; 59: 71-78.
116. Maggioli F, Puricelli G, Dottorini M, et al. The effect of ciprofloxacin on oral contraceptive steroid treatments. Drugs Exp Clin Res 1991; 17: 451-454.
117. Csemiczky G, Alvendal C, Landgren BM. Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with fluoroquinolone (ofloxacin). Adv Contracept 1996; 12: 101-109.
118. Back DJ. Tjia J, Martin C, et al. The lack of interaction between temafloxacin and combined oral contraceptive steroids. Contraception 1991; 43: 317-323.
119. Scholten PC, Droppert RM, Zwinkels MGL, et al. No interaction between ciprofloxacin and an oral contraceptive. Antimicrobial Agents Chemother 1998; 42: 3266-3268.
120. Department of Health. Contraception - Prodigy Guidance 2001. London, UK: Department of Health, 2001.
121. Song S, Chen JK, Yang PJ, et al. A cross-over study of three oral contraceptives containing ethinyl oestradiol and either desogestrel or levonorgestrel. Contraception 1992; 45: 523-532.
122. Cedars MI. Triphasic oral contraceptives: review and comparison of various regimens. Fertil Steril 2002; 77: 1-14.
123. Van Vliet HAAM, Grimes DA, Helmerhorst FM, et al. Biphasic versus triphasic oral contraceptives for contraception (Cochrane Review). The Cochrane Library, Issue 2, 1-2, 2003.
124. Van Vliet HAAM, Grimes DA, Helmerhorst FM, et al. Biphasic versus triphasic oral contraceptives for contraception. Contraception 2002; 65: 321-324.
125. British Medical Association (BMA). Confidentiality and people under 16. Guidance issued jointly by the BMA, GMSC, HEA,Brook Advisory Centres, FPA and RCGP. 1994. BMA Publications online. www.bma.org.uk
126. British Medical Association (BMA). Confidentiality and disclosure of health information. 14 October 1999. BMA Publications online.www.bma.org.uk
127. Little P, Griffin S, Kelly J, et al. Effect of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial. BMJ 1998; 316: 1949-1952.
128. Department of Health. The national sexual health srrategy for health and HIV. Implementation action plan. London, UK: Department of Health Publications, 2002; 1-17.